Sylvester Game Changer Vehicle Among First in Nation to Offer Mobile Prostate Cancer Screening


Newswise – The Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine’s Game Changer vehicles, which provide health education and free screenings for many types of cancer to communities in need in South Florida, are offering prostate-specific antigen (PSA) for the first time. Screening for prostate cancer.

“If we get prostate cancer in the early stages, there is a 95% chance that we can cure it. But if you get prostate cancer, if it’s spread beyond the prostate, there’s only a 25% to 30% chance of survival after five years,” said Brandon Mahal, MD, assistant professor of radiation oncology at Sylvester University. “The PSA is the best screening test we have for detecting cancer early and being able to cure it.”

Black men are at particularly high risk of prostate cancer, which Dr. Mahal makes PSA testing even more important via Sylvester’s mobile units in communities like Little Haiti.

Brandon Mahal, MD

PSA is a simple blood test. Men who get their PSA screenings on the Game Changer typically have their results within 24 hours. They won’t be charged for Game Changer PSA screenings, and those whose results indicate further treatment will be counseled and referred to places where they can access treatment, said Dr. Mahal.

“The Sylvester Office of Outreach and Engagement team and Game Changer program have been providing cancer prevention and screening services to the South Florida community for several years,” said Paco C. Castellon, MPH, MBA, director of Sylvester’s Community Outreach and Engagement program . “A critical component of our program since its inception has been ongoing, two-way engagement with our community stakeholders to understand the needs of the South Florida community. Through this continued involvement in the community, we learned of the community’s interest in prostate cancer screening.

“This initiative, which is a collaboration between the Sylvester Comprehensive Cancer Center, organizations represented in the Southeast Florida Cancer Control Collaborative, and ZERO – The End of Prostate Cancer, underscores the importance of strong partnerships between the community and the university to address the needs of the community, with the aim of achieving equity in health,” said Castellon.

READ:  Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in San Antonio

ZERO – The End of Prostate Cancer is a national non-profit organization with a mission to end prostate cancer and help those affected.

“We are collaborating with Sylvester on the Game Changer prostate cancer awareness program because our mission is to create solutions to achieve health equity to meet the most pressing needs in society,” said Reggie Tucker Seeley, Sc.D., Vice President of Health Justice at ZERO – The End of Prostate Cancer.” This program helps address prostate cancer differences by raising awareness of prostate cancer through our educational materials and resources by offering free PSA screenings through the Game Changer vehicles and connects men to Sylvester if they need follow-up after screening.”

Paco C. Castellon, MPH, MBA

Sylvester’s mobile PSA screening program is one of only two in the US that Dr. Mahal are known. The other started this year at Mount Sinai in New York City.

Sylvester has also partnered with the Southeast Florida Cancer Control Collaborative (SFCCC), a volunteer organization made up of representatives from healthcare provider groups, community organizations, advocacy groups and others involved in networking and education related to cancer control in Broward, Indian River. , Martin, Miami-Dade, Monroe, Okeechobee, Palm Beach and St. Lucie counties.

“We cannot control prostate cancer in Southeast Florida without addressing the disparities that exist in how it is detected,” said Pascale Auguste, who leads the SFCCC Disparities Work Group. “By integrating PSA screening into the Game Changer vehicles, Sylvester will help increase the availability of prostate cancer screening in strategically chosen locations and provide culturally appropriate education, both of which are critical to understanding racial differences in the detection of prostate cancer Tackling prostate cancer in black men. ”

READ:  Smith+Nephew launches OR3O™ Dual Mobility System in Japan for use in primary and revision hip arthroplasty

PSA awareness is key

PSA screening recommendations have changed over the years, and many do not know if or when PSA should be done.

“Recent research suggests that a decline in prostate cancer screening has resulted in an increased incidence of men being diagnosed with metastatic and terminal diseases,” said Sanoj Punnen, MD, MAS, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research, Associate Professor and Associate Chair of Research at Desai Sethi Urology Institute and Co-Chair of the Sylvester Genitourinary Site Disease Group. “The Game Changer will allow us to conduct this valuable screening test in the most vulnerable populations.”

Sanoj Punnen, MD

according to dr Mahal, there has been some controversy surrounding PPE in the past.

“Specifically in 2012, the United States Preventive Services Task Force (USPSTF) issued a recommendation against PSA screening, a Class D recommendation, because two screening studies — one in the US and one in Europe — came out and showed at the time that the number of men who needed PSA screening to save one man’s life was over 1,000,” said Dr. Mahal.

The USPSTF felt that having to screen so many men to save a life detracted from the value of the test.

“The problem with this, and what many prostate cancer experts warned the task force about, was that prostate cancer takes a long time to become a problem. They based the initial recommendation on only seven years of follow-up of PSA studies,” said Dr. Mahal.

Additionally, the task force — which did not include prostate cancer experts — was concerned about overtreatment but underestimated the number of men who can be safely observed in an active surveillance program called active surveillance, thereby avoiding overtreatment and the side effects associated with it, according to Dr . fountains.

READ:  Jeffrey Boscamp Named to NJBIZ ‘Power 50 for Education’

The USPSTF changed its stance in 2018 after 13 years of tracking showed fewer than 800 men needed to be screened to save one man’s life.

Today, according to Dr. Mahal no longer refrains from PSA screening, but leaves the decision to the doctor and patient.

“Nearly all major cancer organizations, including the American Cancer Society, the American Society of Clinical Oncology (ASCO), the Prostate Cancer Foundation, and the American Urological Association, recommend PSA screening primarily for males ages 50 to 70 with specific details of age The range varies depending on the organization making the recommendations,” said Dr. Mahal. “These organizations also agree that higher-risk men should probably start screening around the age of 45. Therefore, in the Game Changer vehicles, we will be targeting high-risk males aged 45-69.”

Sylvester’s Game Changer PSA program has caught the attention of STAMPEDE Prostate Cancer Trial Principal Investigator Nicholas James, MBBS, FRCP, FRCR, Ph.D., Professor of Clinical Oncology at the Institute of Cancer Research at the Royal Marsden Hospital in London drawn .

“We work with Dr. James and colleagues to develop a point-of-care PSA test in the mobile clinic where we would have results immediately. This has never been done before and is just beginning,” said Dr. Mahal.

The Game Changer vehicle offered the prostate cancer screening service on September 10 at La Respectable Loge in Miami and September 13 at the Center for Haitian Studies in Miami. The Game Changer is offering the service on Friday, September 23 from 9 a.m. to 1 p.m. at a back-to-school community event in Liberty City at 6304 NW 14th Avenue, Miami, Florida 33147.

More information on upcoming film screenings can be found here. If you have any questions about Game Changer, get in touch [email protected]





Source link